Regeneron Pharmaceuticals price to sales ratio REGN
Market value divided by revenue over the last twelve months, since 2011.
- Today, Nov 3, 2026
- 6.4×
- 10-year median
- 6.1×
- Against its 10-year history
- 56th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 3.8× to 11.0×
- Peer median
- 7.1×
Regeneron Pharmaceuticals' price to sales ratio is 6.4× as of Nov 3, 2026.
That is above its ten-year median of 6.1×, close to the middle of its last ten years.
Over that time it ranged from 3.8× in May 2025 to 11.0× in Jun 2017.
The median for 9 biotech stocks of a similar size is 7.1×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 6.4× | 4.3× | 6.4× |
| 2025 | 5.8× | 3.8× | 5.8× |
| 2024 | 5.7× | 5.6× | 9.8× |
| 2023 | 7.3× | 5.7× | 7.4× |
| 2022 | 5.7× | 3.8× | 6.1× |
| 2021 | 5.0× | 4.8× | 7.0× |
| 2020 | 6.3× | 4.9× | 9.1× |
| 2019 | 5.4× | 4.2× | 7.3× |
| 2018 | 6.2× | 5.2× | 7.5× |
| 2017 | 7.3× | 7.3× | 11.0× |
| 2016 | 8.2× | 7.6× | 13.4× |
| 2015 | 14.8× | 14.6× | 18.7× |
| 2014 | 16.0× | 12.2× | 16.5× |
| 2013 | 14.4× | 11.3× | 17.5× |
| 2012 | 14.9× | 12.5× | 26.0× |
| 2011 | 11.0× | 9.1× | 12.9× |
Against its peers
Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| REGNRegeneron Pharmaceuticals | 6.4× |
| VRTXVertex Pharmaceuticals | 10.9× |
| ONCBeOne Medicines | 6.6× |
| UTHRUnited Therapeutics | 8.2× |
| INCYIncyte | 4.2× |
| ALNYAlnylam Pharmaceuticals | 4.4× |
| EXELExelixis | 7.1× |
| NBIXNeurocrine Biosciences | 4.4× |
| HALOHalozyme Therapeutics | 8.8× |
| TECHBIO-TECHNE | 9.4× |
| Peer median | 7.1× |
Where Regeneron Pharmaceuticals ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Regeneron Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.